FDA, EMA put a star CAR-T from bluebird and Celgene on the VIP list
During the last ASCO bluebird bio and its partners at Celgene angled into center stage with an update on their BCMA-targeting CAR-T drug bb2121 for multiple myeloma that wowed the cancer crowd.
The FDA as well as European regulators were paying attention. Today the two companies announced that both groups had put the program on their VIP list, with a breakthrough therapy designation right alongside PRIME status.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.